' Remarkable' New Benefit in HER2+ Breast Cancer'Remarkable' New Benefit in HER2+ Breast Cancer
Roughly half of patients with HER2-positive, early stage breast cancer have residual disease after initial drug therapy and then surgery; T-DM1 may improve their outcomes.Medscape Medical News
ConclusionsThe investigative team developed a novel breast cancer treatment DA that is acceptable to women ≥70 years with a history of ER+, HER2-, early stage breast cancer. Next, the DA's efficacy needs to be tested with diverse older women newly diagnosed with breast cancer.
ConclusionAFT does not increase breast cancer recurrence, with the possible exception of late LRRs for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. The use of AFT should not be discouraged.
Metformin, a biguanide, is one of the most commonly prescribed treatments for type 2 diabetes and has recently been recommended as a potential drug candidate for advanced cancer therapy. Although Metformin has...
Publication date: Available online 20 May 2019Source: Trends in Pharmacological SciencesAuthor(s): Mo Yang, John S. SchneeklothRecently, Costales and colleagues (J. Am. Chem. Soc. 2019;141:2960–2974) reported a bivalent small molecule inhibitor of primary miRNA (pri-miR)-515. Perturbation of pri-miR-515 results in the upregulation of HER2 protein levels, rendering HER2– breast cancer cells more sensitive to Herceptin treatment. This strategy represents a novel pharmacological approach to selectively modulating disease-relevant proteins in tumor cells.
ConclusionAlthough well tolerated, the efficacy of everolimus and vinorelbine combination therapy was not superior to vinorelbine monotherapy. There was no correlation between PI3 K mutational status and efficacy.EudracCT No 2011-001024-38, ClinicalTrials.gov No NCT01520103
AbstractTrace amine-associated receptors are G protein-coupled receptors of which TAAR1 is the most well-studied. Recently, Vattai et al. (J Cancer Res Clin Oncol 143:1637 –1647https://doi.org/10.1007/s00432-017-2420-8,2017) reported that expression of TAAR1 may be a marker of breast cancer (BC) survival, with a positive correlation also suggested between TAAR1 expression and HER2 positivity. Neither a role for TAAR1 in breast tissue, nor in cancer, had previously been suspected. We, therefore, sought to provide independent validation and to further examine these putative relationships. First, a bioinformatic analysi...
CONCLUSION: MRI features may predict TIL levels in patients with ER-negative HER-2 positive breast cancer, enhancing the ability to diagnose and treat these patients. PMID: 31109192 [PubMed - as supplied by publisher]
ConclusionSNB application after PST for breast cancer in node positive patients at presentation is increasing. Pre-operative axillary imaging and tumour biology help identify patients who might be candidates for SNB as a single staging procedure.
Publication date: Available online 18 May 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Zoran CuligAbstractEpithelial to mesencyhmal transition (EMT) has a central role in tumor metastasis and progression. EMT is regulated by several growth factors and pro-inflammatory cytokines. The most important role in this regulation could be attributed to transforming growth factor-β (TGF-β). In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 – extracellular-re...